Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Products under Development by Stage of Development | 8 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Products under Development by Therapy Area | 9 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Products under Development by Indication | 10 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Products under Development by Companies | 13 | 2 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Products under Development by Universities/Institutes | 15 | 2 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Companies Involved in Therapeutics Development | 24 | 4 |
| Bayer AG | 24 | 1 |
| Bristol-Myers Squibb Company | 25 | 1 |
| Ionis Pharmaceuticals, Inc. | 26 | 1 |
| LegoChem Biosciences, Inc | 27 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drug Profiles | 28 | 15 |
| AB-012 Drug Profile | 28 | 1 |
| AB-022 Drug Profile | 29 | 1 |
| BAY-1213790 Drug Profile | 30 | 1 |
| BMS-262084 Drug Profile | 31 | 1 |
| BMS-654457 Drug Profile | 32 | 1 |
| coagulation factor XI (human) Drug Profile | 33 | 1 |
| coagulation factor XI (human) Drug Profile | 34 | 1 |
| EP-7041 Drug Profile | 35 | 1 |
| IONIS-FXIRx Drug Profile | 36 | 3 |
| Small Molecule 2 to Inhibit Factor XIa for Thrombosis Drug Profile | 39 | 1 |
| Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders Drug Profile | 40 | 1 |
| Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke Drug Profile | 41 | 1 |
| Small Molecules to Inhibit Factor XIa for Cardiovascular Drug Profile | 42 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Dormant Projects | 43 | 1 |
| Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Featured News &Press Releases | 44 | 7 |
| Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis | 44 | 1 |
| Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022 | 44 | 1 |
| Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery | 45 | 1 |
| Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting | 46 | 1 |
| May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery | 46 | 1 |
| Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma | 47 | 1 |
| Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery | 48 | 1 |
| Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding | 48 | 2 |
| Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders | 50 | 1 |
| Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders | 50 | 1 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |
